Showing results (1181-1190 of 6,501) with videos related to
Sort By:
Pageof 651
Cancer Immunology, Immunotherapy : CII|January 1, 1987
Plant lectin, ATF1011, on the tumor cell surface augments tumor-specific immunity through activation of T cells specific for the lectinR Yoshimoto, N Kondoh, M Isawa, et al.Cancer Immunology, Immunotherapy : CII|January 1, 1986
Uptake of a monoclonal antibody against CEA (Tumak 431/31) in a human colon tumor (Co-112) xenografted in the nude mouse. Dependence on tumor size and injected doseS Duewell, W Horst, G WesteraCancer Immunology, Immunotherapy : CII|January 1, 1986
Effect of dose escalation of a monoclonal anti-CEA IgG on tumour localisation and tissue distribution in nude mice xenografted with human colon carcinomaG T Rogers, R B Pedley, J Boden, et al.Cancer Immunology, Immunotherapy : CII|January 1, 1986
BCG immunotherapy in stage I melanoma patients. Does it influence prognosis determined by HLA-DR expression in high-risk primary tumors?E B Bröcker, L Suter, B M Czarnetzki, et al.Cancer Immunology, Immunotherapy : CII|January 1, 1986
Effects of orally administered retinol on natural killer cell activity in wild type BALB/c and congenitally athymic BALB/c miceL D Fraker, S A Halter, J T ForbesCancer Immunology, Immunotherapy : CII|January 1, 1986
Immunizations against infectious diseases and childhood cancersG W Kneale, A M Stewart, L M WilsonCancer Immunology, Immunotherapy : CII|October 17, 2022
PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for patients with intrahepatic cholangiocarcinomaLavinia Patricia Mocan, Rares Craciun, Cristiana Grapa, et al.Cancer Immunology, Immunotherapy : CII|October 13, 2022
αVEGFR2-MICA fusion antibodies enhance immunotherapy effect and synergize with PD-1 blockadeMingzhu Pan, Fei Wang, Lidi Nan, et al.Cancer Immunology, Immunotherapy : CII|October 10, 2022
Targeting FLT3-specific chimeric antigen receptor T cells for acute lymphoblastic leukemia with KMT2A rearrangementMasaya Suematsu, Shigeki Yagyu, Hideki Yoshida, et al.Cancer Immunology, Immunotherapy : CII|September 14, 2022
Tumor-derived interleukin-34 creates an immunosuppressive and chemoresistant tumor microenvironment by modulating myeloid-derived suppressor cells in triple-negative breast cancerNabeel Kajihara, Takuto Kobayashi, Ryo Otsuka, et al.Pageof 651